- Leading Japanese gene therapy companies are scheduled to visit the Chungju Smart Plant.
- Possibility of collaboration on AAV and pDNA manufacturing ahead of global clinical trials and commercialization.
- Visits from European multinationals and large domestic pharmaceutical companies continue, drawing increased industry attention.
Major gene therapy development companies from Japan are reported to make a series of visits to Reyon Pharmaceutical’s Chungju Smart Plant this coming July. The industry interprets this move as an effort to secure production partners and robust supply chains ahead of global clinical trials and commercialization.
According to industry sources, two representative Japanese gene therapy development companies plan to visit Reyon Pharmaceutical’s Chungju Smart Plant in July. These companies are evaluated as leaders in the Japanese gene therapy sector, each possessing next-generation gene therapy platforms and commercialization experience.
One of the companies is a biopharmaceutical firm whose world-class technical prowess is widely recognized in the field of gene and cell therapy. The company possesses a next-generation degenerative brain disease gene therapy platform based on an adeno-associated virus (AAV) vector capable of crossing the blood-brain barrier (BBB), and is reportedly developing treatments for central nervous system (CNS) disorders such as Alzheimer's disease.
The industry views securing large-scale manufacturing capacity as a critical challenge for this company as it expands global clinical trials and pursues commercialization. At the commercialization stage of gene therapy, large-scale production of AAV vectors is required. In particular, it is essential to secure manufacturing facilities that can stably supply plasmid DNA (pDNA)—the core raw material for AAV production—at a GMP standard.
An industry insider noted, "Gene therapy is a field where manufacturing capabilities, as much as technical prowess, determine business success," adding, "As a company enters late-stage clinical trials and the commercialization phase, securing large-scale production capacity becomes increasingly critical."
The other Japanese company is also understood to be reviewing a visit to the Chungju plant to secure manufacturing infrastructure. This company is one of Japan's first-generation biotech ventures and is known to have experience commercializing a plasmid DNA-based gene therapy. It developed a gene therapy that induces angiogenesis in patients with foot ulcers, and has recently secured positive results in a U.S. Phase 2 clinical trial, reportedly preparing to submit a Biologics License Application (BLA) in the United States.
The industry evaluates that scaling up production and reducing costs have emerged as core tasks for the company ahead of its entry into the U.S. market. A biotech industry expert explained, "The gene therapy industry still faces high manufacturing costs and challenges in mass production," adding, "At the commercialization stage, production yield and cost competitiveness become crucial factors that determine profitability."
Market observers believe that Reyon Pharmaceutical’s Chungju Smart Plant could serve as an attractive option for these Japanese companies. The Chungju Smart Plant is a facility equipped with a one-stop production system capable of everything from plasmid DNA production to viral vector manufacturing and finished drug product processing. Based on large-scale cultivation and purification equipment, it enables GMP-level manufacturing, positioning it as a core hub for expanding the company's CDMO business.
A market analyst stated, "Globally, there are not many facilities capable of end-to-end production from pDNA to finished gene therapy products," adding, "The Chungju plant possesses strong competitiveness in terms of manufacturing infrastructure and scalability, drawing significant interest from global enterprises."
In addition to the Japanese companies, European multinational pharmaceutical firms and large domestic pharmaceutical companies have recently continued to visit the Chungju plant. Its status as a complex manufacturing base equipped with not only biopharmaceutical facilities but also advanced chemical drug production facilities is cited as a key factor attracting attention.
The industry is closely watching whether the upcoming visits by these Japanese companies will move beyond simple site tours and lead to actual manufacturing collaborations. Given that these visits are being made by companies driving late-stage clinical trials and commercialization, they are expected to serve as an opportunity to validate the CDMO competitiveness of the Chungju Smart Plant.
